The Diamedix immunosimplicity EBV (Epstein-Barr Virus) test kits are a panel of ELISA tests for the detection of IgG and IgM antibodies to VCA (Viral Capsid Antigen), for IgG and IgM antibodies to EA-D (Early Antigen Diffuse) and for IgG and IgM antibodies to EBNA-1 (Epstein-Barr Nuclear Antigen-1).
These tests, for the qualitative and semi-quantitative determination of antibodies to EBV, have been manufactured and FDA-cleared for performance either manually or in conjunction with this company’s MAGO Plus Automated EIA Processor. The tests monitor antibody patterns, which can be of diagnostic importance in the assessment of potential EBV-related infectious mononucleosis.
Color-coded reagents with matching caps are ready for either manual or automated use. Three room-temperature incubations provide test results within about 90 minutes. The kit’s standard 96-microwell-plate format adapts well to large-volume laboratories while its breakapart strip format provides small-volume flexibility. They also can be batch-tested concurrently with other EIA assays. The procedure requires minimal hands-on time. The colored end products are measured spectrophotometrically, yielding objective results that denote antibody presence/absence in the sample.
Results for sera classified by other commercially available ELISA kits and the heterophile antibody test indicated that 94 to 100 percent of the seronegative sera were negative in all tests in the panel. Sera from current infections were positive for VCA IgM (95 percent), VCA IgG (85 percent) and EA-D (40 percent) while predominantly (87 percent) negative for EBNA IgG. Convalescent (past infection) sera were negative for VCA IgM and EBNA IgM (97 percent and 97 percent) and EA-D IgG (90 percent) and positive for ENBA IgG (98 percent) and VCA IgG (100 percent).Diamedix Corp.
